Gentileschi, S., Barreca, C., Bellisai, F., Biasi, G., Brizi, M.G., De Stefano, R., et al. (2016). Switch from infliximab to infliximab biosimilar: efficacy and safety in a cohort of patients with different rheumatic diseases: Response to: Nikiphorou E, Kautiainen H, Hannonen P, et al. Clinical effectiveness of CT-P13 (Infliximab biosimilar) used as a switch from Remicade (infliximab) in patients with established rheumatic disease. Report of clinical experience based on prospective observational data. Expert Opin Biol Ther. 2015;15:1677–1683. EXPERT OPINION ON BIOLOGICAL THERAPY, 16(10), 1311-1312 [10.1080/14712598.2016.1198765].
Switch from infliximab to infliximab biosimilar: efficacy and safety in a cohort of patients with different rheumatic diseases: Response to: Nikiphorou E, Kautiainen H, Hannonen P, et al. Clinical effectiveness of CT-P13 (Infliximab biosimilar) used as a switch from Remicade (infliximab) in patients with established rheumatic disease. Report of clinical experience based on prospective observational data. Expert Opin Biol Ther. 2015;15:1677–1683
Gentileschi, Stefano;BELLISAI, FRANCESCA;FABBRONI, MARTA;FIORAVANTI, ANTONELLA;FRATI, ELENA;Vitale, Antonio;CANTARINI, LUCA;FREDIANI, BRUNO;GALEAZZI, MAURO
2016-01-01
| File | Dimensione | Formato | |
|---|---|---|---|
|
Frati ranking 1.pdf
non disponibili
Tipologia:
PDF editoriale
Licenza:
NON PUBBLICO - Accesso privato/ristretto
Dimensione
1.17 MB
Formato
Adobe PDF
|
1.17 MB | Adobe PDF | Visualizza/Apri Richiedi una copia |
|
FRATI-Switch from infliximab-Post--Print.pdf
accesso aperto
Descrizione: Accepted Manuscript
Tipologia:
Post-print
Licenza:
Creative commons
Dimensione
147.88 kB
Formato
Adobe PDF
|
147.88 kB | Adobe PDF | Visualizza/Apri |
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
https://hdl.handle.net/11365/996417